Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orismilast
- Development stage
- Phase 2
- Lead developer
- UNION therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Orismilast is a next-generation, high-potency, oral small molecule inhibitor of phosphodiesterase 4 (PDE4), with selectivity for the PDE4B and PDE4D subtypes. By inhibiting these enzymes, orismilast reduces the breakdown of cyclic AMP (cAMP), leading to broad anti-inflammatory effects through modulation of Th1, Th2, and Th17 pathways and suppression of multiple pro-inflammatory cytokines. Orismilast is being developed primarily for immunological and dermatological diseases including atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis, and ulcerative colitis. It has demonstrated efficacy in phase II trials for AD and is also being studied in other inflammatory conditions. The drug is designed as a modified-release tablet to improve tolerability by minimizing gastrointestinal side effects commonly associated with PDE4 inhibition[1][2][9][10].
- Other names
- orismilastORISMILAST [INN]UNII-JH1CX8SG5VUNII-JH-1CX8SG5VUNII-JH 1CX8SG5V
02
Targets
PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4D (Phosphodiesterase 4D)
Beyond the preview
Go deeper on orismilast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orismilast.